Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.
Shah V, Peters A, Umpierrez G, Sherr J, Akturk H, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs P, Lal R, Mader J, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho C, Ayers A, Tian T, Aaron R, Klonoff D. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. Journal Of Diabetes Science And Technology 2024, 19322968241291512. PMID: 39517127, DOI: 10.1177/19322968241291512.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RA therapyGLP-1RAGLP-1RAsType 1 diabetesReceptor agonistsAdjunctive therapyAbsence of randomized controlled trialsIncreasing prevalence of obesityUS Food and Drug AdministrationRisk of severe hypoglycemiaEffective adjunctive therapyPrevalence of obesityTreatment of T1DFood and Drug AdministrationRandomized controlled trialsDiabetic ketoacidosisAdjunctive treatmentMetabolic outcomesSevere hypoglycemiaAutomated insulin deliveryConsensus reportDrug AdministrationTherapy